The lawsuit, filed by the law firm Glancy Prongay Wolke & Rotter LLP, centers on allegations that Zoetis misled shareholders between January 14, 2025, and May 6, 2026. The complaint asserts that the company concealed a sharp decline in the adoption of Librela, its canine pain treatment, following FDA safety warnings regarding neurological complications.
Investors Eye Lead Role in Zoetis Securities Fraud Suit
Investors who sustained financial losses from Zoetis Inc. stock are being invited to step forward as lead plaintiffs in a looming securities fraud class action. The legal window to join the litigation against the veterinary pharmaceutical firm closes on July 27, 2026, marking a critical deadline for affected shareholders.
Beyond Librela, the litigation claims that the company’s broader product portfolio faced undisclosed competitive pressures. Specifically, the suit alleges that Simparica Trio lost significant market share to lower-priced alternatives, while dermatology products Apoquel and Cytopoint struggled against newly launched rivals. Plaintiffs argue that these omissions rendered the company's public statements regarding its business operations materially misleading throughout the specified period. Investors interested in the action or their legal standing may contact Charles Linehan at the firm’s Los Angeles office.
Comments (0)
No comments yet. Be the first!